Nexalin Technology (NXL) Cash from Operations (2021 - 2026)
Nexalin Technology's (NXL) quarterly Cash from Operations came in at 1712988.0 in Q1 2026, down 20.11% year-on-year from 2144112.43 in Q1 2025, and down 49.21% quarter-over-quarter from 1148022.0 in Q4 2025.
Nexalin Technology (NXL) Cash from Operations (2021 - 2026) Analysis & Trends
Nexalin Technology's Cash from Operations history runs 6 years deep, the most recent figure standing at 1712988.0 for Q1 2026.
- On a quarterly basis, Cash from Operations fell 20.11% year-over-year to 1712988.0 in Q1 2026; TTM through Mar 2026 was 5244432.0, a 13.83% decrease from a year earlier, with the FY2025 full-year figure at 4957658.0, down 25.69% from the prior year.
- Cash from Operations declined to 1712988.0 in Q1 2026 per NXL's latest filing, from 1148022.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 162272.0 in Q2 2022 and bottomed at 1712988.0 in Q1 2026.
- The 5-year median for Cash from Operations is 943699.0 (2022), against an average of 980359.94.
- Across the five-year window, Cash from Operations sank 546.75% in 2023 and soared 41.94% in 2024, its largest moves.
- Year by year, Cash from Operations stood at 906457.0 in 2022, then retreated by 10.76% to 1004030.0 in 2023, then slipped by 12.99% to 1134476.0 in 2024, then declined by 1.19% to 1148022.0 in 2025, then sank by 49.21% to 1712988.0 in 2026.
- Per Business Quant, the three latest NXL Cash from Operations figures stand at 1712988.0 (Q1 2026), 1148022.0 (Q4 2025), and 1466257.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.32 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 581.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 2.57 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 348.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 43.80 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 525.60 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 220.10 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 290.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Nexalin Technology | 9.32 Mn | 6.61 Mn | 13,133.00 | -1.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.71 Mn |
| Mar 31, 2026 | -1.71 Mn |
| Dec 31, 2025 | -1.15 Mn |
| Dec 31, 2025 | -1.15 Mn |
| Sep 30, 2025 | -1.47 Mn |
| Sep 30, 2025 | -1.47 Mn |
| Jun 30, 2025 | -917,165.00 |
| Jun 30, 2025 | -917,165.00 |
| Mar 31, 2025 | -1.43 Mn |
| Mar 31, 2025 | -1.43 Mn |
| Dec 31, 2024 | -1.13 Mn |
| Dec 31, 2024 | -1.13 Mn |
| Sep 30, 2024 | -800,210.00 |
| Sep 30, 2024 | -800,210.00 |
| Jun 30, 2024 | -1.25 Mn |
| Jun 30, 2024 | -1.25 Mn |
| Mar 31, 2024 | -763,289.00 |
| Mar 31, 2024 | -763,289.00 |
| Dec 31, 2023 | -1.00 Mn |
| Dec 31, 2023 | -1.00 Mn |